Sivik Global Healthcare LLC Invests $1.19 Million in Alnylam Pharmaceuticals, Inc. $ALNY

Sivik Global Healthcare LLC purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,193,000.

Other hedge funds have also recently bought and sold shares of the company. Thematics Asset Management bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $1,995,000. Mediolanum International Funds Ltd bought a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $11,389,000. Rakuten Investment Management Inc. bought a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $14,205,000. Generali Asset Management SPA SGR grew its holdings in shares of Alnylam Pharmaceuticals by 6,368.0% during the third quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock worth $1,475,000 after buying an additional 3,184 shares in the last quarter. Finally, Investment Management Corp of Ontario grew its holdings in shares of Alnylam Pharmaceuticals by 35.4% during the second quarter. Investment Management Corp of Ontario now owns 31,521 shares of the biopharmaceutical company’s stock worth $10,279,000 after buying an additional 8,244 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Alnylam Pharmaceuticals

In other news, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider owned 9,443 shares in the company, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Jeffrey V. Poulton sold 2,206 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $722,795.90. Following the sale, the executive vice president owned 64,273 shares of the company’s stock, valued at approximately $21,059,048.45. This represents a 3.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 57,833 shares of company stock valued at $19,346,441. Insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 3.3%

ALNY stock opened at $319.52 on Wednesday. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $42.38 billion, a PE ratio of 186.85 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55. The business’s 50 day simple moving average is $325.44 and its 200 day simple moving average is $392.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period in the previous year, the firm posted ($0.65) earnings per share. The firm’s revenue was up 84.9% compared to the same quarter last year. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ALNY shares. Barclays started coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price objective for the company. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Truist Financial reduced their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Canaccord Genuity Group increased their price objective on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Finally, Weiss Ratings downgraded shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $473.87.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.